Read More Pharma Industry News Merck (NYSE: MRK) reports Q2 loss, hikes revenue view as Keytruda Qlex ramps Merck raised 2026 sales guidance to $67.3B but cut EPS to $2.76 on Terns charge. Lipfendra approval and $463M Keytruda Qlex quarter reshape the 2028 cliff. byVenkateshAugust 5, 2026